SCHEMBL3333888

SCHEMBL3333888

Cc1nccc2c3ccccc3n(C)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.59
MAOA P21397 2/20 0.59
BCHE P06276 2/20 0.59
ACHE P22303 2/20 0.59
ALKBH5 Q6P6C2 1/20 0.58
FTO Q9C0B1 1/20 0.58
GPR3 P46089 1/20 0.52
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
GABRP O00591 2/20 0.45
GABRD O14764 2/20 0.45
GABRA1 P14867 2/20 0.45
GABRB1 P18505 2/20 0.45
GABRG2 P18507 2/20 0.45
GABRB3 P28472 2/20 0.45
GABRA5 P31644 2/20 0.45
GABRA3 P34903 2/20 0.45
GABRA2 P47869 2/20 0.45
GABRB2 P47870 2/20 0.45
GABRA4 P48169 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20340614 0.83 DYRK1A (0.53) DYRK1AHASPIN
SCHEMBL21168174 0.82 DYRK1A (0.57) DYRK1AMAOABCHEACHECYP2A6
SCHEMBL27992450 0.81 ALKBH5 (0.51) DYRK1AMAOABCHEACHEALKBH5
SCHEMBL3339645 0.81 ALKBH5 (0.51) DYRK1AMAOABCHEACHEALKBH5
SCHEMBL16596110 0.81 ALKBH5 (0.51) DYRK1AMAOABCHEACHEALKBH5
SCHEMBL3340225 0.81 ALKBH5 (0.51) DYRK1AMAOABCHEACHEALKBH5
SCHEMBL17502378 0.80 HASPIN (0.59) DYRK1AHASPIN
SCHEMBL17517490 0.80 HASPIN (0.55) DYRK1AHASPIN
SCHEMBL28928549 0.80 ACHE (0.60) DYRK1AMAOABCHEACHEALKBH5
SCHEMBL17517548 0.79 CYP1A2 (0.52) DYRK1AMAOAACHEHASPINCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9107914-B2 Beta-carbolines for use in the treatment of hearing loss and vertigo AUDIOCURE PHARMA GMBH (DE) 2015-08-18 US claimed
EP-2519238-B1 BETA-CARBOLINES FOR THE TREATMENT OF HEARING LOSS AND VERTIGO AUDIOCURE PHARMA GMBH (DE) 2014-08-13 EP claimed
US-20130028958-A1 BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO AUDIOCURE PHARMA GMBH (DE) 2013-01-31 US claimed
CN-102146080-B Beta-carboline alkali derivative compounds and application thereof XINJIANG HUASHIDAN PHARMACEUTICAL CO LTD 2013-01-30 CN claimed
US-8334299-B2 β-carboline for the treatment of neurodegenerative diseases ELLNEUROXX, LTD. (DE) 2012-12-18 US claimed
US-20100143474-A1 B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ELLNEUROXX, LTD. 2010-06-10 US claimed
US-12018037-B2 Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-06-25 US disclosed
US-20230192738-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-06-22 US disclosed
EP-2125812-B2 USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ELLNEUROXX LTD (DE) 2016-05-25 EP disclosed
EP-2924042-A1 BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) 2015-09-30 EP disclosed
CN-104177376-A 1-Position diamine beta-carboline alkali compound, and preparation method, medicinal composition and use thereof XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD 2014-12-03 CN disclosed
EP-2519238-B1 BETA-CARBOLINES FOR THE TREATMENT OF HEARING LOSS AND VERTIGO AUDIOCURE PHARMA GMBH (DE) 2014-08-13 EP disclosed
US-8334299-B2 β-carboline for the treatment of neurodegenerative diseases ELLNEUROXX, LTD. (DE) 2012-12-18 US disclosed
US-8334299-B2 β-carboline for the treatment of neurodegenerative diseases ELLNEUROXX, LTD. (DE) 2012-12-18 US disclosed
EP-2125812-B1 USE OF ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ELLNEUROXX LTD (DE) 2012-10-31 EP disclosed
WO-2011079841-A1 BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO ROMMELSPACHER HANS (DE) 2011-07-07 WO disclosed
US-20100143474-A1 B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ELLNEUROXX, LTD. 2010-06-10 US disclosed
US-20100143474-A1 B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ELLNEUROXX, LTD. 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130028958-A1 BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO CBFB, ADRA2B, SLC6A12 DYRK1A 4232/4885MAOA 2170/4885BCHE 92/4885
US-20100143474-A1 B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, SNCA, CHAT DYRK1A 2361/4885MAOA 130/4885BCHE 4/4885
US-12018037-B2 Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound ORC3, LEF1, OCIAD1 DYRK1A 4634/4885MAOA 2906/4885BCHE 3072/4885
US-20230192738-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OPRM1, OPRD1, OXER1 DYRK1A 2151/4885MAOA 1209/4885BCHE 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.